Gilead Calistoga LLC
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 3 name spellings.
4
Ending by 2030
Nov 2029
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Apr 15, 2027The maintenance fee for Polymorphic Forms of a Hydrochloride Salt of (S)-2-(1-(9H-PURIN-6-Ylamino)PROPYL)-5-Fluoro-3-Phenylquinazolin-4(3H)-ONE (US 10,442,805) comes due Apr 15, 2027. Unpaid by Oct 15, 2027, it lapses early.
- 1 fee due Jun 29, 2027The maintenance fee for Phosphatidylinositol 3-Kinase Inhibitors (US 9,221,795) comes due Jun 29, 2027. Unpaid by Dec 29, 2027, it lapses early.
- 1 fee due Jul 19, 2027The maintenance fee for Therapies for hematologic malignancies (US 9,238,070) comes due Jul 19, 2027. Unpaid by Jan 19, 2028, it lapses early.
- 1 fee due Aug 23, 2027The maintenance fee for Phosphatidylinositol 3-kinase inhibitors (US 9,266,878) comes due Aug 23, 2027. Unpaid by Feb 23, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,154,998 | Therapies for hematologic malignancies In force · USPTO record | In force | USPTO record | |
| US 9,492,449 | Therapies for hematologic malignancies In force · USPTO record | In force | USPTO record | |
| US 9,238,070 | Therapies for hematologic malignancies In force · USPTO record | In force | USPTO record | |
| US 8,691,829 | Treatment of liver disorders with PI3K inhibitors In force · USPTO record | In force | USPTO record | |
| US 8,865,730 | Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one In force · USPTO record | In force | USPTO record | |
| US 10,730,879 | Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one In force · USPTO record | In force | USPTO record | |
| US 9,469,643 | Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one In force · USPTO record | In force | USPTO record | |
| US 9,018,221 | Phosphatidylinositol 3-Kinase Inhibitors In force · High confidence | In force | High confidence | |
| US 9,029,384 | Phosphatidylinositol 3-Kinase Inhibitors In force · High confidence | In force | High confidence | |
| US 9,266,878 | Phosphatidylinositol 3-kinase inhibitors In force · USPTO record | In force | USPTO record |
Also on record, not counted in the 16: 2 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 abandoned · 10 no status recorded